Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Enrolling by invitation · Phase 2/Phase 3

Conditions studied: Autism Spectrum Disorder

In brief

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.

Key facts

Study ID

NCT05494398

Run by

Stanford University

People needed

144

Starts

2024-03-12

Expected to finish

2029-01-31

Last updated by the study team

2026-05-15

Who can join

Age: 3 and older, up to 13. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• participation in an associated single-dose (IRB-54931, NCT04278898) or randomized, controlled trial of NAC (IRB- 68353, NCT05664789).
• stable medication regimens (≥ 30 days) with no anticipated changes during the trial.

You may not qualify if…

• the presence of significant medical problems that reduce medical stability.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.